Eli Lilly and Company $LLY Shares Bought by Rooted Wealth Advisors Inc.

Rooted Wealth Advisors Inc. grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 276.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,510 shares of the company’s stock after purchasing an additional 1,109 shares during the period. Rooted Wealth Advisors Inc.’s holdings in Eli Lilly and Company were worth $1,389,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in LLY. Brighton Jones LLC grew its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares in the last quarter. Schnieders Capital Management LLC. increased its position in shares of Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after buying an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth $356,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth $749,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.1%

LLY stock opened at $1,206.51 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company has a market cap of $1.14 trillion, a price-to-earnings ratio of 42.86, a PEG ratio of 1.32 and a beta of 0.53. The business has a fifty day simple moving average of $1,036.28 and a 200-day simple moving average of $1,021.13. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,215.76.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter last year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LLY. Guggenheim reissued a “buy” rating and issued a $1,183.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a report on Friday, March 6th. Weiss Ratings lowered shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, May 19th. HSBC cut shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their price objective for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Finally, Barclays upped their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,235.07.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.